报价延迟最少15分钟:2026/09/03 13:41 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
0.2776 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-4.46/-0.75
|
|
企业价值
3.75M
|
| 资产负债 |
|
每股账面净值
-0.18
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
131.00K
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
同行比较之报价最少15分钟延迟 (夜盘时段除外)
|
业务概览
|
|||
| VivoSim Labs Inc is a pharmaceutical and biotechnology services company focused on testing drugs and drug candidates in three-dimensional human tissue models of the liver and intestine. The Company provides liver and intestinal toxicology insights using its new approach methodologies and models and offers liver toxicology predictive screening and research services, as well as services to predict and study the intestinal side effect profiles of therapeutic candidates at all stages of drug development. Its 3D human tissue platform includes expertise in 3D organoids, such as spheroids, and proprietary cell culture techniques. |
